Satellos Bioscience (MSCL) Q3 2025 earnings summary

Executive summary

• Appointed Mark Nawacki, an experienced M&A executive, to the Board of Directors to support growth and clinical development.

• Advanced SAT-3247 clinical program with IND submission to the FDA and global filings for a Phase 2 trial in pediatric DMD.

• Dosed first patient in a long-term follow-up study (LT-001) of SAT-3247 in adults with DMD.

Financial highlights

• Ended Q3 2025 with $34.6 million in cash and equivalents, down from $48.5 million at year-end 2024.

• Reported Q3 2025 net loss of $5.8 million ($0.03/share), improved from $6.6 million ($0.06/share) in Q3 2024.

• R&D expenses rose to $4.0 million from $2.4 million year-over-year, driven by increased clinical trial costs.

• G&A expenses increased to $2.0 million from $1.3 million year-over-year, mainly due to higher headcount and stock-based compensation.

Outlook and guidance

• Plans to enroll the first patient in the global Phase 2 pediatric DMD study by end of 2025.

• Initial results from LT-001 long-term follow-up study expected in Q1 2026.

• LT-001 study expansion into the United States is planned.